Expanding the Diversity of Allosteric Bcr-Abl Inhibitors

Title
Expanding the Diversity of Allosteric Bcr-Abl Inhibitors
Authors
Xianming DengBarun OkramQiang DingJianming ZhangYongmun ChoiFrancisco J. AdrinAmy WojciechowskiGuobao ZhangJianwei CheBadry BursulayaSandra W. Cowan-JacoGabriele Rummel심태보Nathanael S. Gray
Issue Date
2010-10
Publisher
Journal of medicinal chemistry
Citation
VOL 53, NO 19, 6934-6946
Abstract
Inhibition of Bcr-Abl kinase activity by imatinib for the treatment of chronic myeloid leukemia (CML) currently serves as the paradigm for targeting dominant oncogenes with small molecules. We recently reported the discovery of GNF-2 (1) and GNF-5 (2) as selective non-ATP competitive inhibitors of cellular Bcr-Abl kinase activity that target the myristate binding site. Here, we used cell-based structure-activity relationships to guide the optimization and diversification of ligands that are capable of binding to the myristate binding site and rationalize the findings based upon an Abl-compound 1 cocrystal.We elucidate the structure-activity relationships required to obtain potent antiproliferative activity against Bcr-Abl transformed cells and report the discovery of new compounds (5g, 5h, 6a, 14d, and 21j-I) that display improved potency or pharmacological properties. This work demonstrates that a variety of structures can effectively target the Bcr-Abl myristate binding site and provides new leads for developing drugs that can target this binding site.
URI
http://pubs.kist.re.kr/handle/201004/41894
ISSN
0022-2623
Appears in Collections:
KIST Publication > Article
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE